Persistence of immunity following a booster dose of Haemophilus influenzae type B-meningococcal serogroup C glycoconjugate vaccine: Follow-up of a randomized controlled trial

Pediatric Infectious Disease Journal

Volumn 30, Issue 3, 2011, Pages 197-202

  Khatami, Ameneh ^a   Snape, Matthew D ^a   John, Tessa ^a   Westcar, Sharon ^a   Klinger, Chaam ^a   Rollinson, Llinos ^a   Boutriau, Dominique ^b   Mesaros, Narcisa ^b   Wysocki, Jacek ^c,d   Galaj, Andrzej ^e   Yu, Ly Mee ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c Specjalistyczny Zespol Opieki Nad Matka I Dzeckiem   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e VITAMED   (Poland)

Author keywords

immunity; meningococcal; persistence; serogroup C; vaccine

Indexed keywords

DIPHTHERIA TOXOID CRM197; GLYCOCONJUGATE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE;

ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAEMOPHILUS INFECTION; HUMAN; IMMUNITY; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TODDLER;

EID: 79951681571     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181f728fd     Document Type: Article

References (36)

1. Campbell H, Borrow R, Salisbury D, et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(suppl 2): B20-B29.
2. Snape MD, Kelly DF, Green B, et al. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J. 2005;24:128-131. (Pubitemid 40250770)
3. Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence following serogroup C meningococcal conjugate immunization of UK primary school children in 1999 to 2000 and response to a booster. Clin Infect Dis. 2010;15:1601-1610.
4. Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17:840-847.
5. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-367. (Pubitemid 38970013)
6. Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA. 2000;284:2334-2340.
7. Trotter CL, McVernon J, Andrews NJ, et al. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet. 2003;361:1523-1524. (Pubitemid 36566347)
8. Ramsay ME, McVernon J, Andrews NJ, et al. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis. 2003;188:481-485. (Pubitemid 37011798)
9. Pace D, Snape M, Westcar S, et al. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Arch Dis Child. 2008;93:963-970.
10. Pace D, Snape M, Westcar S, et al. A new combination Haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. Pediatr Infect Dis J. 2007;26:1057-1059. (Pubitemid 350287591)
11. Eskola J, Käyhty H, Peltola H, et al. Antibody levels achieved in infants by course of Haemophilus influenzae type B polysaccharide/diphtheria toxoid conjugate vaccine. Lancet. 1985;1:1184-1186. (Pubitemid 15083672)
12. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1984;149:1034-1035.
13. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780-786. (Pubitemid 37129487)
14. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine. 2005;23:2222-2227. (Pubitemid 40341456)
15. Caro JJ, Möller J, Getsios D, et al. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health. 2007;7:130-141.
16. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J. 2001;20:153-159. (Pubitemid 32151937)
17. Kelly DF, Snape MD, Clutterbuck EA, et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood. 2006;108:2642-2647.
18. Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis. 2006;43:1387-1394. (Pubitemid 44845637)
19. McVernon J, MacLennan J, Pollard AJ, et al. Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatr Infect Dis J. 2003;22:659-661. (Pubitemid 36900217)
20. McVernon J, Johnson PD, Pollard AJ, et al. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch Dis Child. 2003;88:379-383. (Pubitemid 36566716)
21. Blanchard Rohner G, Snape MD, Kelly DF, et al. The magnitude of the antibody and memory B cell responses during priming with a protein- polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol. 2008;180:2165-2173.
22. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9:213-220.
23. Baltimore RS. Recent trends in meningococcal epidemiology and current vaccine recommendations. Curr Opin Pediatr. 2006;18:58-63. (Pubitemid 43790890)
24. MacLennan J, Kafatos G, Neal K, et al. United Kingdom Meningococcal Carriage Group. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. 2006;12:950-957. (Pubitemid 43848417)
25. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17:154-159.
26. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis. 2001;183:160-163. (Pubitemid 32043057)
27. Díez-Domingo J, Cantarino MV, Torrentí JM, et al. MenC Study Group. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J. 2010;29:148-152.
28. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326:365-366. (Pubitemid 36241472)
29. Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737-743. (Pubitemid 351364476)
30. Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev. 2007;31:5263.
31. Eskola J, Ward J, Dagan R, et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet. 1999;354:2063-2068.
32. Hallander HO, Gustafsson L. Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience. Expert Rev Vaccines. 2009;8:1303-1307.
33. Kitchin N, Southern J, Morris R, et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine. 2009;27:5096-5102.
34. Zinke M, Disselhoff J, Gartner B, et al. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Hum Vaccine. 2010;6. [Epub ahead of print].
35. Mallet E, Matisse N, Mathieu N, et al. Pentavac Study Group. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine. 2004;22:1415-1422. (Pubitemid 38446917)
36. Carlsson RM, Claesson BA, Fagerlund E, et al. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J. 2002;21:535-541. (Pubitemid 34625835)